These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23188892)

  • 1. Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study.
    Venskutonyte L; Brismar K; Rydén-Bergsten T; Rydén L; Kjellström B
    Diab Vasc Dis Res; 2013 May; 10(3):263-9. PubMed ID: 23188892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
    Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
    Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
    Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
    Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
    Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
    Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.
    Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
    J Intern Med; 2010 Jul; 268(1):75-82. PubMed ID: 20210844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].
    Gustafsson I; Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt PR; MacLeod K; Laakso M; Torp-Pedersen CT; Waldenström A;
    Ugeskr Laeger; 2006 Feb; 168(6):581-4. PubMed ID: 16476220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.
    Mukherjee AK; Reddy VS; Shah S; Jhingan AK; Ramakrishnan P; Prusty V; Singh NS
    J Indian Med Assoc; 2009 Jul; 107(7):464-70. PubMed ID: 20112854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.
    Peyrot M; Rubin RR; Polonsky WH; Best JH
    Curr Med Res Opin; 2010 May; 26(5):1047-54. PubMed ID: 20199136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C; Gilbride CJ
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
    Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
    Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nutritional and metabolic status and dietetic evaluation in institutionalized elderly patients with non-insulin-dependent diabetes mellitus].
    Casimiro C; García de Lorenzo A; Usán L;
    Nutr Hosp; 2001; 16(3):104-11. PubMed ID: 11475679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.